Rotigotine Hydrochloride
Code | Size | Price |
---|
TAR-T21446-5mg | 5mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T21446-1mL | 1 mL * 10 mM (in DMSO) | £117.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T21446-10mg | 10mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T21446-25mg | 25mg | £149.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T21446-50mg | 50mg | £183.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T21446-100mg | 100mg | £228.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Rotigotine Hydrochloride, a dopamine receptor agonist prefering for D3 receptors over D1 and D2, has effective activity of anti-Parkinsonian. Racemic rotigotine hydrochloride is about 50 times as potent as quinpirole, the gold standard D2 agonist.
CAS:
125572-93-2
Formula:
C19H26ClNOS
Molecular Weight:
351.93
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9966
SMILES:
Cl.CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1
Target:
Dopamine Receptor; 5-HT Receptor; Adrenergic Receptor
References
1. Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. J Parkinsons Dis. 2016 Apr 2. [Epub ahead of print] PubMed PMID: 27061066.
2. Cannas A, Meloni M, Mascia MM,et al. Priapism and Hypersexuality Associated With Rotigotine in an Elderly Parkinsonian Patient: A Case Report. Clin Neuropharmacol. 2016 Apr 4. [Epub ahead of print] PubMed PMID: 27046660.
3. LeWitt PA, Poewe W, Elmer LW, et al. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93.
4. Dauvilliers Y, Benes H, Partinen M, Rauta V, Rifkin D, Dohin E, Goldammer N, Schollmayer E, Schr?der H, Winkelman JW. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. Am J Kidney Dis. 2016 Feb 2. pii: S0272-6386(16)00018-4.